ArticleTropical medicine and health2025
Epidemiology of moderate-to-severe respiratory syncytial virus infections in children in subtropical Okinawa, Japan: a 4-year retrospective study.
Article in Tropical medicine and health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Epidemiology and clinical impact of pediatric RSV co-infections after the COVID-19 pandemic: a narrative review.Frontiers in pediatrics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRespiratory syncytial virus (RSV) is a leading cause of acute lower respiratory tract infections (ALRTIs) in infants and young children worldwide. While its epidemiology is well-characterized in temperate climates, data from subtropical regions such as Okinawa, Japan, remain limited. This study aimed to describe the clinical and demographic characteristics, risk factors, and seasonality of moderate-to-severe RSV infections in children under 5 years across Okinawa.
methodsThis retrospective, multicenter study analyzed pediatric cases of laboratoryconfirmed RSV infection requiring hospitalization between April 2017 and March 2021. Data were collected from four core hospitals across Okinawa Prefecture. Patients were categorized as having moderate or severe disease based on ICU admission status. Demographic variables, underlying diseases, household and childcare characteristics, and seasonal trends were assessed.
resultsA total of 1541 hospitalized RSV cases were included, of which 117 (7.6%) were classified as severe. Overall, 89.0% were under 24 months of age, with the highest burden in the 0-2 month group. In univariate analysis, severe cases were significantly younger, more likely to have siblings, and less likely to attend nursery school compared with moderate cases. The overall prevalence of underlying diseases did not differ between groups; however, having two or more underlying diseases was significantly associated with severity. Multivariate logistic regression confirmed younger age, the presence of siblings, and underlying diseases (both any and multiple) as independent risk factors for severe infection. Seasonal peaks occurred consistently in summer during 2017-2019. In contrast, in 2020, coinciding with the onset of the COVID-19 pandemic, the epidemic curve became broader and peak timings varied across hospitals. Overall, the total number of cases decreased by 62% compared with the pre-pandemic average.
conclusionsThis study provides a comprehensive region-wide assessment of moderate-to-severe pediatric RSV infections in a subtropical setting in Japan. Despite not including data on the use of palivizumab, nirsevimab, or maternal vaccination, the findings provide essential baseline data to guide the implementation of new preventive strategies tailored to local epidemiology.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.